Copley Scientific

Copley Scientific supplies a range of equipment, software and services for inhaled product testing for every stage of development and manufacture, of both innovator and generic products, topical and systemic. It is also a provider of test instrumentation for other dosage forms.

Headquarters
Copley Scientific Ltd
Colwick Quays Business Park
Nottingham
NG4 2JY
United Kingdom

Phone / Contact

T: +44 115 961 6229
F: +44 115 961 7637
E: [email protected]

Connect

Copley Scientific is a leading manufacturer of inhaler test equipment and a trusted provider of test instrumentation for other pharmaceutical dosage forms including tablets, capsules, transdermals, semisolids, powders, suppositories and equipment for detergent testing.

The company works closely with industry groups and experts to bring relevant new products to market. All of its equipment is backed by expert training and lifetime support.

It has 1,200 customers across 96 countries, including nine of the world’s 10 largest pharmaceutical companies.

Copley Scientific was founded in 1946 in Nottingham, UK, and is still family owned and managed today. Company headquarters remains in Nottingham in a purpose-built facility, with a well-established sales and service company in Switzerland.

Articles by Copley Scientific

BETTER IN VIVO PREDICTION FROM OINDP TESTING: A GOAL WORTH PURSUING?

Matthew Fenn and Clair Brooks, consider the motivation for adopting more clinically representative test set-ups in orally inhaled and nasal drug product development and, more specifically, for the demonstration of bioequivalence, as well as the practicalities of doing so and the tools available to support such efforts.

PERFECT TIMING FOR THE AUTOMATION OF OINDP TESTING

Adam Smith and Clair Brooks take a look at the benefits of automation, focusing on the actuation of metered dose inhalers and multidose nasal sprays/aerosols.

IMPROVING IN VITRO TEST METHODS FOR NASAL DRUG PRODUCTS

Mark Copley and Anna Sipitanou look at how in vitro testing is being refined for greater repeatability to maximise its value as a low-cost tool for product development, including an assessment of the role of automation in improving the sensitivity of in vitro testing.

SEMI-AUTOMATION IN INHALER TESTING – EXPLORING THE POTENTIAL AND PRACTICALITIES

João Pereira, Raquel Borda D’Água, Mark Copley and Anna Sipitanou, discuss the semi-automation of cascade impactor testing and the benefits it can bring in terms of quality of orally inhaled product test data, and reductions in cost and effort associated with routine, critical measurements.

VARIABILITY IN CASCADE IMPACTION: SOURCES, IMPACT AND STRATEGIES FOR REDUCTION

Mark Copley considers cascade impaction as a method for determining the aerodynamic particle size distribution of orally inhaled drug products, and how techniques to improve air flow control and semi-automation of the process can significantly reduce the variability involved.

COMPANY SHOWCASE: NOVI

In December 2015 the inhaler automation specialists Novi Systems launched their latest product, a ten-way shake and fire system for pMDIs called DecaVertus. Novi continues to innovate, bringing efficiency, precision and repeatability to inhalation labs around the world.

OPTIMISING IN VITRO TESTING FOR TRANSDERMAL AND TOPICAL DRUG PRODUCTS

Tony Copley examines the regulatory framework for transdermal and topical products and popular, effective and cost-efficient in vitro testing techniques for quantifying their release characteristics.

A NEW, ADVANCED HIGH-THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING

Adam Smith introduces DecaVertus, describing its single inhaler predecessor the Vertus, and how the DecaVertus design evolved using the Vertus technology.

IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING

Mark Copley provides some background on mouth-throat models for OIP testing.

Top